Hjem › Multipelt myelom › Texas › Dallas
Kliniske studier for Multipelt myelom i Dallas, TX
17 studier for Multipelt myelom søker deltakere på steder i og rundt Dallas (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekruttererFase 3
- Research Site, Dallas
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 3
- Baylor University Medical Center, Dallas
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 3
- Baylor University Medical Center, Dallas
- UT Southwestern Medical Center, Dallas
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekruttererFase 3
- University of Texas Southwestern Medical Center, Dallas
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 2
- UT Southwestern Medical Center, Dallas
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RekruttererFase 1/2
- University of Texas - Southwestern Medical Center /ID# 271914, Dallas
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RekruttererFase 3
- Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
- Baylor University Medical Center, Dallas
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RekruttererFase 1
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekruttererFase 1/2
- Research Site, Dallas
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RekruttererFase 3
- Research Site, Dallas
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
RekruttererFase 1
- Baylor University Medical Center, Dallas
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RekruttererFase 1/2
- University of Texas - Southwestern Medical Center /ID# 274360, Dallas
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 1
- Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
RekruttererFase 1
- University of Texas Southwestern, Dallas
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
RekruttererFase 2
- University of Texas Southwestern, Dallas
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
RekruttererObservasjonsstudie
- Ut Southwestern, Dallas
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RekruttererFase 1
- University of Texas Southwestern Medical Center, Dallas
Multipelt myelom-studier i andre byer
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA41 studier
- Houston, TX38 studier
- Durham, NC37 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- Rochester, MN24 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Chicago, IL22 studier
Andre studier i Dallas
- Brystkreft55 studier
- Ikke-småcellet lungekreft52 studier
- Metastatisk kreft42 studier
- Hjertesvikt42 studier
- Kreft (alle typer)37 studier
- Prostatakreft36 studier
- Kolorektal kreft33 studier
- Fedme30 studier
- Eggstokkreft28 studier
- Blærekreft27 studier
- Lungekreft27 studier
- Endometriekreft24 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.